Cue Biopharma (CUE) Stock Price, News & Analysis

Company Overview

Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders.

The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.

Based in Cambridge, Massachusetts, Cue Biopharma works in the biotechnology sector. Its approach focuses on engineering biologics to shape the body’s T-cell response rather than broadly activating or suppressing the immune system.

Key Stats

• Today's Range: $14.30 to $17.69
• 50-Day Range: $16.08 to $37.84
• 52-Week Range: $4.97 to $45.50
• Volume: 274,902 shs
• Average Volume: 134,746 shs
• Market Capitalization: $117.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $83.00
• Consensus Rating: Hold

Cue Biopharma Stock Analysis - MarketRank™

Cue Biopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 510th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Cue Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cue Biopharma has a consensus price target of $83.00, representing about 414.9% upside from its current price of $16.12.

Amount of Analyst Coverage

Cue Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cue Biopharma are expected to grow in the coming year, from ($21.79) to ($8.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cue Biopharma is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cue Biopharma is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cue Biopharma has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.90% of the float of Cue Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 7.57.

Change versus previous month

Short interest in Cue Biopharma has recently increased by 8.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cue Biopharma does not currently pay a dividend.

Dividend Growth

Cue Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

Cue Biopharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cue Biopharma this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

4 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cue Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,260.00 in company stock.

Percentage Held by Insiders

14.56% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.04% of the stock of Cue Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CUE
• CIK: 1645460
• Web: www.cuebiopharma.com
• Phone: (617) 949-2680
• Fax: N/A
• Employees: 29
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Cue Biopharma: $83.00
• High Price Target: $83.00
• Low Price Target: $83.00
• Potential Upside/Downside: +414.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($27.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.60 million
• Net Margins: -435.83%
• Pretax Margin: -434.50%
• Return on Equity: -620.06%
• Return on Assets: -291.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.25
• Quick Ratio: 1.25

Sales & Book Value

• Annual Sales: $27.47 million
• Price / Sales: 4.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.08 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 7,260,000
• Free Float: 6,206,000
• Market Cap: $117.03 million
• Optionable: No Data
• Beta: 2.79